<DOC>
	<DOCNO>NCT02274376</DOCNO>
	<brief_summary>This observational study collect prospective data safety tolerability Xeloda patient advance gastric cancer every day clinical practice . Documentation treatment patient continue end treatment per oncologist 's assessment .</brief_summary>
	<brief_title>Non-Interventional Study Xeloda ( Capecitabine ) Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Patients age &gt; /=18 year , metastatic gastric cancer available prospective documentation treatment ( firstline chemotherapy ) Informed consent Contraindications Xeloda per Summary Product Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>